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Abstract 
The aim of this study is to evaluate effective prognostic factors in the evolution of patients with retroperitoneal fibrosis and to 
establish the validity of fractal analysis in determining the disease severity in these patients.  
Material and Methods:  This study included 19 patients (M/F: 5/14) treated for idiopathic retroperitoneal fibrosis and bilateral 
obstructive renal failure between Jan 2004-Dec 2008. Patients were identified retrospectively, searching for patients diagnosed with 
IRF, after retroperitoneal biopsy or, in most cases the diagnosis rested on radiological findings, especially CT, with identification of a 
retroperitoneal mass, the absence of other demonstrable renal or ureteric disease or any other pathology that could explain the 
findings. CT was very useful in describing the retroperitoneal mass around the aorta and inferior vena cava, the extent of the lesion 
and for monitoring the response to surgical treatment during the follow-up. The data were evaluated about medical history, physical 
examination findings, laboratory tests (serum urea and creatinine, blood sugar, sodium, potassium, bicarbonate levels, serum pH, 
uric acid, haematocrit, white blood cell count), imaging methods (renal ultrasound, abdominal CT-scan, MRI). At admission all 
patients had active disease with obstructive renal failure and underwent bilateral ureteric stenting in order to normalize the BUN 
levels. After normalizing of BUN levels, ureterolysis and omental wrapping was performed. Postoperatively, ureteric stents were 
removed after 1month and remission of renal disfunction was obtained in approximately 5 months (range 2-10 months). All patients 
were followed for at least 1 year. Patients were regularly checked every 3 months.  
Results: Of the 19 patients, there were 5 men and 14 women. The median age at diagnosis of RF was 50 years (range 42–64 
years). The most frequent presenting symptoms were back or abdominal pain, weakness, weight loss, oligoanuria, arterial 
hypertension and mild fever. The duration of symptoms before diagnosis ranged from 6 to 18 months. At presentation all patients 
had active disease, presenting renal dysfunction with a median serum creatinine of 5.18 mg/dl (range 1-15.4 mg/dl). Most of the 
patients had moderate bilateral hydronephrosis (2nd degree hydronephrosis). In our study, all patients had excellent prognosis, with 
full recovery of renal function in 78% of cases (15 patients).  The fractal dimension of the fibrosis mass contour correlates with level 
of renal function impairment. Even more, the fractal dimension seems to slightly variate between CT evaluations (1.30 ±0.1), 
suggesting a non aggressive pattern of extension of the fibrotic mass characteristic for benign lesions.  
Conclusions: The imaging parameters did not predict the disease severity, except the increase in fractal dimension of fibrosis 
surface area.  Efficacy of bilateral ureteric stenting in improving renal function is limited in most of the cases. Dispite the level of renal 
function impairment at admission, full recovery can be achieved after bilateral ureteric stenting/nephrostomy and ureterolisis. 
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Introduction
Retroperitoneal fibrosis (RPF) was first described in 
1905 by the French urologist Albaran, but it became fully 
recognized in 1948, with the classic publication by 
Ormond [1]. Although its true incidence is unknown, 
estimates range from one case per 200,000 to 500,000 
individuals per year. [2] It occurs predominantly in men in 
their fifth and sixth decades of life, with a 3:1 male/female 
ratio, and no ethnic predisposition.[3] Retroperitoneal 
fibrosis is generally idiopathic, but can also be secondary 
to the use of certain drugs, malignant diseases, infections 
and surgery. The idiopathic form of the disease accounts 
for more than two thirds of cases and it is characterized by 
a white, woody and fibrous plaque that covers the 
retroperitoneal structures, i.e. the great vessels, ureters 
and the psoas muscle. It is usually centralized at the level 
of the fourth and fifth lumbar vertebrae and spread down 
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to the pelvis; rarely, it extends into the roots of the 
mesentery, scrotum or continues above the diaphragm as 
fibrous mediastinitis. [1–3] 
The clinical presentation of IRF is usually insidious 
with vague constitutional symptoms and generally low 
back pain that may be severe and non-responsive to anti-
inflammatory drugs. The pathogenesis is still poorly 
elucidated, but recent evidence supports the hypothesis 
that the disease may be the result of an inflammatory 
state triggered by autoimmune responses [8–10]. Parum 
et al. [8], considering the high correlation of IRF with 
atheromatous peri-aortitis, considers that the disease may 
be due to an immune reaction to some components of 
atherosclerotic plaques such as low-density lipoprotein 
(LDL) and ceroid.   
The introduction of medical therapy, mainly based 
on corticosteroids, has greatly improved patients’ 
outcome,[5,6] and the availability of imaging techniques, 
such as computer tomography (CT) and magnetic 
resonance imaging (MRI), has provided non-invasive and 
reliable methods of diagnosis and follow-up. [7] 
The aim of this study is to evaluate effective 
prognostic factors in the evolution of patients with 
retroperitoneal fibrosis and to establish the validity of 
fractal analysis in determining the disease severity in 
these patients. Both surgical and medical managements 
have been used in IRF. There are two main approaches; 
the first consists of surgical relief of the obstruction by 
ureterolysis (open or laparoscopic) with or without omental 
wrapping of the ureter, followed or not by corticosteroid 
therapy [6]. The second consists of relieving the 
obstruction by placing ureteric stent(s), followed by 
corticosteroid therapy alone or together with azathioprine 
or tamoxifen [6]. However, there are no prospective 
randomized trials to compare the two alternatives. 
 
Material and methods 
This study included 19 patients (M/F: 5/14) treated 
for idiopathic retroperitoneal fibrosis and bilateral 
obstructive renal failure between Jan 2004-Dec 2008. 
Patients were identified retrospectively, by searching for 
the ones diagnosed with IRF, after retroperitoneal biopsy 
or, in most cases the diagnosis resting on radiological 
findings, especially CT, with the identification of a 
retroperitoneal mass, the absence of other demonstrable 
renal or ureteric disease or any other pathology that could 
explain the findings. CT was very useful in describing the 
retroperitoneal mass around the aorta and inferior vena 
cava, the extent of the lesion and for monitoring the 
response to surgical treatment during the follow-up. The 
data about medical history, physical examination findings, 
laboratory tests (serum urea and creatinine, blood sugar, 
sodium, potassium, bicarbonate levels, serum pH, uric 
acid, haematocrit, white blood cell count), imaging 
methods (renal echography, abdominal CT-scan, MRI) 
were evaluated. 
All patients were followed for at least 1 year. 
Patients were regularly checked at every 3 months. At 
each control, patients were submitted to clinical 
examination and to the following laboratory tests: serum 
creatinine, complete blood cell count and urine analysis. 
Renal ultrasound and computed tomography (CT) were 
performed every 6 months until the achievement of 
remission. After remission, the same investigations were 
repeated every year.  
At admission, all patients had active disease with 
obstructive renal failure and underwent bilateral ureteric 
stenting in order to normalize the BUN levels.  CT scan 
was performed on a helical Siemens Emotions 2007 with 
16 slices preoperatory in all cases and images were 
processed in the Department of Radiology of “Fundeni” 
Clinical Institute. Parameters assessed on helical CT 
were: level of secondary hydronephrosis, fibrosis width in 
the transureteric frontal section, interureteric distance at 
L4 intervertebral discus, maximal cranio-caudal length in 
frontal section of fibrosis area and the fractal dimension of 
fibrosis mass. According to the level of renal function 
impairment we used native or contrast enhanced images. 
At six months, contrast CT was performed at 
patients with normal renal function. Maximal cranio-caudal 
length was calculated in frontal sections and was 
considered as the maximal vertical extension of the fibrotic 
mass. Because the ICV and the abdominal aorta are not 
visible on frontal reconstructive section native CT scan, 
we considered the ureters as landmarks and the fibrotic 
mass occupying the space between the 2 ureters with a 
lateral extension beyond the line that crosses the ureters. 
The ureteric distance in native CT was calculated with the 
help of the ureteric stents. The width of the fibrotic mass 
was considered the line between the lateral extensions of 
the fibrotic mass at L4 intervertebral discus in a 
longitudinal section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Multiplanar frontal reconstruction in native CT scan 
after bilateral ureteric stenting (transureteric section) 
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Fractal analysis  
In the last 10 years fractal analysis become a 
powerful tool for analyzing form, pattern and growth of 
biological systems and subsystems at microscopic and 
macroscopic scale [18, 19]. In our case, the fractal 
dimension can give information on the irregularity of the 
contour of the fibrosis masses.  This kind of details are 
best captured by using the box counting method which 
provides us with a measure - fractal dimension (Fd) of the 
non/ smoothness of the contour. The fractal dimension is 
calculated by using the „box-counting” algorithm because, 
in comparison to other methods, it  offers two major 
advantages: it is easy to implement and can be applied on 
no matter how complex images.  
 
Method description 
The „box-counting” algorithm [20] assumes the 
determination of the fractal dimension in accordance with 
the dependence of the object contour upon the used 
measure scale factor. It consists of successive image 
coverage with grids of squares of sides 2, 4, 8. It is 
important to constantly count the number of squares that 
contain parts of the contour. The points of coordinates 
(log(N(s)), log(1/s)), where s is the common side of the 
coverage squares, and N(s)  the number of squares that 
contain the information, will be positioned approximately in 
a line and its slope will be the fractal dimension in “box-
counting”  sense.  
Thus, the “box-counting” fractal dimension, derived 
from the Hausdorff coverage dimension [16, 17] is given 
by the following approximation: 
, 
 
 
where  - N(s) is the number of squares that contain 
information (parts of the extracted contour).  
- s - side length of the squares in the coverage 
grid. 
It is expected, that for a smaller s, the above 
approximation should be better, 
0
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If this limit exists, it is called the “box-counting” 
dimension of the measured object. In practice, this limit 
converges slowly, that is why the following expression is 
used:  
1
log( ( )) log Ns F d
s
⎛⎞ =⋅⎜⎟
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This is the equation of a straight line of slope Fd, the 
“log-log” curve described by the points of (log(N(s), 
log(1/s)) for different values of the cube’s side -s. Through 
linear regression (least squares method), the slope of the 
line that  approximates the points’ distribution is 
determined; this is the fractal dimension.  
For an example of how the algorithm is used, we will 
consider the image of a region of the fibrosis mass for 
which we want to determine the fractal dimension of the 
contour – Fig. 1.1. Traditionally, in order to determine the 
contour, the pixels over certain luminosity are being 
neglected  Fig. 1.2.a); this implies choosing a good 
threshold in order to capture the exact object of interest. 
When applying this procedure to medical images like CTs 
and MRIs, the errors can be larger than the extracted 
information itself. That is why we implemented a different 
method for contour extraction.  The contour is captured at 
a series of different levels of luminosity Fig. 1.2.b) – this 
method leading to better performances and being a novel 
approach towards macroscopic medical images 
processing. The different levels of luminosity are chosen 
within the range of shades of the analyzed object. 
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Fig. 2. 1. The initial image; 2. extracted contour 
a) – classical method; b)– proposed method 
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Next, we will apply the “box-counting” 
algorithm, described above, for different scale values s, 
using a software tool- MorfoFractal developed along with 
the contour extraction tool.  
We have used images that contain those parts 
of the fibrosis mass that are not obstructed by nearby 
organs, so that we can obtain information on the free 
evolution of the mass.  We took the CT from each patient, 
which contains as many such fibrosis regions and 
calculated the global fractal dimension. 
Results 
Clinical characteristics at presentation  
Out of the 19 patients, 5 were men and 14 women. 
The median age at diagnosis of RF was 50 years old 
(range 42–64 years old). The most frequent presenting 
symptoms were back or abdominal pain, weakness, 
weight loss, oligoanuria, arterial hypertension and mild 
fever (Table 1). The duration of symptoms before 
diagnosis ranged from 6 to 18 months. At presentation all 
patients had active disease, presenting renal dysfunction 
with a median serum creatinine of 5,18 mg/dl (range 1-
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The diagnosis of IRF was made by CT in all patients 
and confirmed with a histological evaluation of the fibrotic 
mass. The biopsy of the mass was obtained during 
ureterolysis. At admission, all patients had active disease 
with obstructive renal failure and underwent bilateral 
ureteric stenting in order to normalize the BUN levels. 
After the normalizing of BUN levels, ureterolysis and 
omental wrapping was performed. Postoperatively, 
ureteric stents were removed after 1mth and remission of 
renal dysfunction was obtained in approximately 5 months 
(range 2-10 months). 
15.4 mg/dl). Five of them had a rapidly progressive renal 
failure with a serum creatinine (8.2mg/dl) and were oliguric 
or anuric at presentation. The median haematocrit of the 
patients group was 33% (range 29–40%). 
 
 
 
 
 
Table I. Clinical and laboratory characteristics at presentation 
of patients 
 
Sex M/F  5/14 
Age (year)  50 (42–64) 
Creatinine (mg/dl)  5,18 (1-15.4) 
Haematocrit (%)  33 (29–40) 
Loin pain  15 
Weight loss/weakness  10 
Oliguria/Anuria  5 
Fever  3 
We used bilateral ureteric stenting for all patients in 
order not only to normalize the BUN levels, but also to 
establish the landmarks on the native CT and to facilitate 
intraoperative dissection of the ureters. Five of our 
patients needed unilateral percutaneous nephrosthomy 
due to the inefficiency of bilateral stenting. 
   
 
 
 
 
Table II. CT characteristics and serum creatinine values during follow-up 
 
   UHN level*    Fibrosis width  Interureteric 
distance  
Cranio-caudal 
length 
Fractal dimension  Serum creatinine 
   Preop  1  
mth 
6 
mth 
Preop  1 
mth 
6 
mth 
Preop  1 
mth 
6 
mth 
Preop  1 
mth 
6 
mth 
Preop  1 
mth 
6  
mth 
Preop  1 
mth 
6 
mth 
1  2  2  0  3.88  0  -  7.5  12.8  11  13.6  8.6  -  1.29  -  -  2.4  1.1  0.7 
2  2  1  1  6.22  5.4  -  6.2  12.4  12  16.2  10  4.3  1.28  1.23  -  2.3  1.2  1.3 
3  3  3  1  5.82  0  -  5.7  11.4  11  10.2  4.5  -  1.43  -  -  4.2  1.6  1.3 
4  3  2  1  6.47  5.4  3,4  5.2  14.2  14  12.6  8.6  6.1  1.42  1.32  1.28  4.5  1.5  1.5 
5  2  1  1  3.15  0  -  8.2  13.2  13  14.3  10  8.2  1.39  -  -  4.5  1.4  1.3 
6  2  2  1  7.27  7.2  -  7.2  10.4  9.5  10.6  5.6  -  1.38  1.36  -  4.3  2  1.1 
7  2  1  0  5.53  3.1  -  8  8.2  8.6  7.8  4.4  -  1.36  1.31  -  3.8  1.1  1 
8  1  1  2  6.31  5.8  -  6.3  7.4  7.2  10.4  14  13  1.25  1.15  -  1  1.2  1.6 
9  1  1  1  7.34  0  -  7.3  -  8.4  5.4  5.6  5.4  1.28  -  -  1.1  -  1.6 
10  4  2  1  5.6  5.5  -  4.3  7.5  7.5  12.6  8.5  -  1.6  1.41  -  15.4  3.7  1.7 
11  4  1  1  5.6  4.2  3,1  5.6  7.2  7.4  5.4  -  -  1.49  1.45  1.36  6.8  2.1  1.4 
12  3  2  1  6.3  3.4  3,4  6.5  10.4  10  5.6  5.6  4.8  1.55  1.49  1.39  10.6  1.7  1.1 
13  2  1  0  6.7  0  -  5.8  7.6  7.2  6.3  -  -  1.46  -  -  5.6  2.1  0.7 
14  2  1  0  8.2  4.3  -  5.6  8.5  8.2  10.5  4.8  -  1.37  1.28  -  3.1  0.8  0.7 
15  2  1  0  6.3  6.4  3,1  6.3  6.3  6.3  7.8  -  -  1.3  1.29  1.22  3.1  0.9  1 
16  3  0  0  6.4  0  3,1  6.3  -  8.4  10.4  -  6.4  1.38  -  1.1  3.6  0.9  1 
17  2  1  0  5.7  4.5  -  5.7  8.4  -  5.1  -  -  1.53  -  1.32  6.9  0.9  0.7 
18  3  1  1  8.4  4.7  4,4  7.2  -  8.8  13.1  -  8.4  1.58  -  -  10  1.1  0.9 
19  4  2  1  7.4  5.8  -  5.8  10.2  -  7.4  7.4  -  1.47  1.44  -  5.4  1.1  1.2 
Median  2  1  1  6.24  5.1  3.4  6.35  9.8  9.4  9.56  9.8  6.8  1.41  1.33  1.06  5.18  3  1.1 
 
  Median UHN  Median ureteric distance  Median fibrosis width  Fractal dimension  Serum creatinine 
Preop  2  6.35  6.24  1.41  5.18 
1 month  1  9.75  5.05  1.33  2.76 
6 months  1  9.56  3.41  1.27  1.14 
 
Most of the patients had moderate bilateral hydronephrosis (2nd degree hydronephrosis). In our study, all patients 
had excellent prognosis, with full recovery of renal function in 15 patients (78%).  
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The fractal dimension of the fibrosis mass correlates 
with the level of renal function impairment suggested by 
the creatinine level. Generally, in the case of preoperatory 
analyzed CTs, if the creatinine value is high, the fractal 
dimension is higher too, but the rate of increase in the 
case of Fd is lower as it can be deduced from Fig 3. This 
fact leads to our statement that the more aggressive the 
fibrosis (high Fd), the higher the level of renal function 
impairment. 
The fractal dimension varies suggestively between 
CT evaluations in time (1.30 ±0.2), suggesting a non-
aggressive pattern of extension of the fibrotic mass 
characteristic for benign lesions. In fact, the regression of 
the affected tissue width and structure complexity (Fd) can 
be clearly observed. 
After the surgical intervention, it can be observed 
that the value of the fractal dimension of the mass is 
decreasing with approximately the same rate as the 
fibrosis width. The decrease in Fd results from the fact 
that the fibrosis contour is becoming smoother along with 
area diminution.  Generally, the creatinine levels are 
dropping too, but much faster, mainly due to the presence 
of ureteric stents/nephrostomy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interureteric distance and fibrosis width at admission 
do not correlate with the serum creatinine value (fig.4, fig 
5.) and the recovery of the renal function, these confirming 
previous studies on RF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5. Serum creatinine levels vs. fibrosis width at 
admission 
 
Discussion 
Malignancy was excluded based on clinical, 
laboratory and radiological grounds. CT scan did not show 
any direct sign of malignancy or indirect signs such as 
cranial location of the mass, anterior displacement of the 
aorta, lateral displacement of the ureters and/or bone 
destruction [13] 
All the patients had ureterolysis and omental 
wrapping. The advantages of surgery are the relief of 
obstruction with a recovery of renal function in about 70% 
of cases [11] and the possibility of taking samples of the 
invading mass to rule out lymphomas or metastatic 
cancer. However, obstruction may recur in about 22% of 
responders [12]. Moreover, surgery does not relieve the 
systemic manifestations of the disease that affect the 
majority of patients, symptoms that can be managed by 
the use of cortisone or immunosuppressive agents. 
Generally, however, ureterolysis remains the mainstay in 
treatment of this disease. The ureter is dissected free from 
the plaque, and in order to prevent it from being caught 
again by the fibrotic process laterally or intraperitoneally. 
An alternative procedure is to wrap the ureter with 
omentum to provide an effective barrier against re-
entrapment by the fibrosis [15]. Postoperative CT in cases 
in which an omental wrap has been used shows a low-
attenuation halo surrounding the opaque ureter [15].  
Fig.3 Creatinine vs. Fractal dimension 
Patients who have had ureterolysis commonly have 
a lateral bowing of the mid-portion of the ureter(s) [15]. 
Long-term follow-up with CT usually shows a progressive 
decrease in the size of the plaque, especially in patients 
treated with corticosteroids. However, the majority of 
patients will have a small residual mass that can persist 
for months to years [14].  
Fig 4. Serum creatinine levels vs. hydronephrosis degree at 
admission. 
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Fig. 6a  Fig. 6b 
Fig. 6. Postoperatory CT scans at 3 and 6 months. In figure A, low-attenuation halo is observed around the right ureter. Figure 
B, full remission of fibrotic mass at 6 months after surgery. 
 
Neither sufficient information is available on the 
long-term outcome of patients with RF, nor is there any 
study that compares the efficacy of different therapeutic 
options. In our study, most of our patients had excellent 
prognosis, with full recovery of renal function in 15 
patients (78%). Four of our patients remained with one 
functional kidney, 2 required permanent ureteric stent and 
2 nephrostomy with a mild but stable renal insufficiency 
(serum creatinine level >1.5 mg/dl). 
Conclusions 
The imaging parameters did not predict the disease  
 
severity, except for the increase in fractal dimension of 
fibrosis surface area.  Efficacy of bilateral ureteric stenting 
in improving renal function is limited in most of the cases. 
Despite the level of renal function impairment at 
admission, full recovery can be achieved after bilateral 
ureteric stenting/nephrostomy and ureterolisis. However, 
as renal insufficiency may persist and local reactivations 
or other possible complications of the disease may occur, 
patients with IRF should be regularly monitored by CT 
scan at 6 months and should receive a prompt 
therapeutical intervention in order to treat the recurrences 
of the disease. 
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